BioCentury
ARTICLE | Company News

Radius Health scores with Express Scripts 2018 formulary

July 31, 2017 9:17 PM UTC

Radius Health Inc. (NASDAQ:RDUS) gained $1.90 to $44.03 Monday after Express Scripts Holding Co. (NASDAQ:ESRX) listed Radius' osteoporosis drug Tymlos abaloparatide-SC as a preferred alternative to Forteo teriparatide from Eli Lilly and Co. (NYSE:LLY). The PBM posted a list of drugs it will not cover in its 2018 National Preferred Formulary, along with preferred alternatives in each drug category. The new formulary excluded 64 additional drugs over 2017, bringing the total exclusions to 159.

FDA approved Tymlos, a subcutaneous peptide analog of PTH-related protein (PTHrP), in April to treat osteoporosis in postmenopausal women at high risk for fracture. Forteo is a human parathyroid hormone (PTH) fragment (see BioCentury Extra, April 28)...